LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
115.20
-1.30 (-1.12%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close116.50
Open116.23
Bid113.26 x 1100
Ask114.20 x 800
Day's Range114.14 - 116.65
52 Week Range77.09 - 132.13
Volume9,604,948
Avg. Volume17,148,824
Market Cap111.838B
Beta (3Y Monthly)0.54
PE Ratio (TTM)36.81
EPS (TTM)3.13
Earnings DateApr 30, 2019
Forward Dividend & Yield2.58 (1.99%)
Ex-Dividend Date2019-02-14
1y Target Est124.93
Trade prices are not sourced from all markets
  • TheStreet.com16 hours ago

    Jim Cramer: Diversification Is Good for Offense, Not Just Defense

    This selloff, which actually started at the end of the last quarter, has taken apart the managed care stocks, the drug stocks, the devices and finally the biotechs. No matter, the fact is that every day there were moments in this tsunami where you simply couldn't believe the torrent of selling, but you most likely didn't even know what was going to spring a leak next. Being diversified is defensive, as we know: If you had all health care bought in March, you might be done for 2019! But I think, more important and less talked about, it allows you to be offensive, too.

  • MarketWatch17 hours ago

    Pfizer, Lilly shares decline as osteoarthritis drug misses goals in study

    Shares of drug makers Pfizer Inc. and Eli Lilly & Co. declined in the extended session Thursday after the companies said a clinical study of an osteoarthritis drug didn't meet certain goals. Pfizer shares declined 1% after hours, following a 1.3% decline to close at $39.38 in the regular trading session. Lilly shares fell 1.9% after hours, following a 1.1% close lower at $115.20. The companies said that a late-stage study of their drug tanezumab at 5 mg did not show a statistically significant improvement in overall osteoarthritis symptoms compared with nonsteroidal anti-inflammatory drugs. A 2.5 mg dose did not show a statistically significant improvement in pain, physical function or patients' overall assessment, the companies said. "We are analyzing these findings in the context of the recent Phase 3 results as we assess potential next steps for tanezumab," said Ken Verburg, Pfizer's tanezumab development team leader, in a statement. "We plan to review the totality of data from our clinical development program for tanezumab with regulatory authorities."

  • Reuters17 hours ago

    Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study

    A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday. The drug, tanezumab, belongs to a new category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and has been touted as a potential blockbuster. The study tested the treatment in two doses, 2.5 mg and 5 mg, comparing the long-term joint safety and effectiveness at the end of 16 weeks with painkillers that are normally prescribed to patients.

  • Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
    Zacksyesterday

    Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline

    Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.

  • Double Top Spells Trouble for 3 Health Care Stocks
    Investopedia2 days ago

    Double Top Spells Trouble for 3 Health Care Stocks

    Health care stocks have fallen out of favor due to sector rotation and political pressure. Explore three trading ideas to benefit from falling prices.

  • Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales
    Zacks3 days ago

    Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales

    Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.

  • J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
    Zacks4 days ago

    J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer

    FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months

  • Biotechnology Market on a Tear: 5 ETFs in Spotlight
    Zacks8 days ago

    Biotechnology Market on a Tear: 5 ETFs in Spotlight

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

  • Barrons.com8 days ago

    Eli Lilly Stock Was Downgraded Because Everyone Already Knows It’s Good

    (LLY) stock was lower on Thursday following a downgrade from Guggenheim, which argues that the drugmaker’s strong growth outlook is already baked into the shares. Many health-care stocks had a good 2018 as tech lost its luster and the market swoon sent investors scrambling for safety, but few have fared better than Eli Lilly. Although the stock is up just under 9% in 2019, slightly trailing the broader market’s gains, it has risen 58% in the trailing 12-month period.

  • The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors
    Zacks8 days ago

    The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors

    The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors

  • CNBC8 days ago

    Here are the biggest analyst calls of the day: Apple, Chipotle, IBM, Xerox, U.S. Steel & more

    Here are the biggest calls on Wall Street on Thursday

  • MoneyShow8 days ago

    Algorithms, Derivatives and Manias- A Day of Reckoning

    Stocks bottomed in March 2009. From April 2009 through the end of 2018, more than $878 billion flowed out of equity mutual funds, $778 in just the last four years, observes market timing specialist Alan Newman, editor of CrossCurrents.

  • Lilly Confirms Date and Conference Call for First-Quarter 2019 Financial Results Announcement
    PR Newswire9 days ago

    Lilly Confirms Date and Conference Call for First-Quarter 2019 Financial Results Announcement

    INDIANAPOLIS , April 10, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2019 financial results on Tuesday, April 30, 2019 . Lilly will also conduct a conference ...

  • Top Stock Reports for Eli Lilly, Altria & Becton Dickinson
    Zacks9 days ago

    Top Stock Reports for Eli Lilly, Altria & Becton Dickinson

    Top Stock Reports for Eli Lilly, Altria & Becton Dickinson

  • Is AstraZeneca Stock Worth Buying Before Earnings?
    InvestorPlace9 days ago

    Is AstraZeneca Stock Worth Buying Before Earnings?

    Last year's extreme sentiment fears have abated and now the equity markets are back near all-time highs. This includes stocks like AstraZeneca (NYSE:AZN) as it set a new high late last month. From that standpoint, this is not an obvious entry point into AZN stock, but whether you should buy the stock also depends on a few other factors.Source: Shutterstock Those who want to own AZN shares for the long term can afford to ignore short-term downside risk. But for most other investors who prefer to start an ownership position into a stock in the green should be slightly more surgical than just jumping in at any time.AZN stock is on a tear up 11% in 12 months. But the company will report earnings on April 26 and those events are wild. So this makes buying the stock now a short-term binary bet. Reactions to earnings scorecards are usually more to do with expectations than the actual value of a stock.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBefore you label me a hater, my caution for AstraZeneca stock here is not a dis against the company itself or its prospects. I am merely concerned with buying into a stock that is not likely to fall soon thereafter. Looking back on its prior reactions to earnings, they are split. * 10 Dow Jones Stocks Holding the Blue Chip Index Back Last quarter, the stock spiked drastically on the results, which left a giant open gap in the chart. Although this does not happen all of the time, Wall Street usually likes to fill these gaps.Since the spike to all-time highs, AZN stock has been drifting lower and testing recent support. If it loses $40 per share, it risks triggering a bearish pattern that would close the gap below. Although this is not a forecast, it is a scenario that could unfold here and investors need to be aware of it.The good news is that $39 per share is a mid-term pivot level and those tend to lend support on the way down. These are zones that the bulls and bears find interesting, so they will fight it out and create price congestion. How to Approach AZN Stock NowSo far my reservation to owning the shares immediately has been technically based. Fundamentally, AZN stock is not cheap as it sells at a price-to-earnings ratio of 47. This is more than three times as expensive as Bristol-Myers Squibb (NYSE:BMY) and twice as expensive as Apple (NASDAQ:AAPL) … to draw absolute and relative comparisons, respectively.Moreover, healthcare and biotech stocks are back in the sights of the political rifles. This is the only current bipartisan consensus topic. Both Democrats and Republicans want to vilify and persecute the drug companies. The rhetoric of both sides involves bringing legislation that would bring down the price of medicine and change the current Health Care Act. * 7 Vulnerable Stocks to Watch On Brexit News and Trade Wars These are nervous times on Wall Street. The S&P 500 has been on an extended run since the December crash and that makes investors nervous. Almost everyone I hear in the media suggests that traders are ready to sell at the first sign of trouble. So the prevailing idea is that we've come too far too fast. For some reason, they didn't say that on the way down, when last year we fell even faster and farther.But for now, we have to respect the collective and be cautious. This is not an obvious time to load up on new positions of AZN stock, even if it means I would miss out on a few upside dollars if it rips. And for those who already own AstraZeneca stock, it's not an alarm to sell out of the position. Furthermore, the options markets offer many ways I can temporarily defend my shares by selling covered calls or buying puts. Doing both would be a dollar neutral strategy.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Medical Marijuana Stocks to Cure Your Portfolio * 8 Best Stocks to Buy for an April Rally * Top 20 Stocks to Buy for 20-Somethings! Compare Brokers The post Is AstraZeneca Stock Worth Buying Before Earnings? appeared first on InvestorPlace.

  • CNBC9 days ago

    Sanofi sets a fixed price of insulin at $99 per month for some patients

    The move is a pre-emptive one as the French drugmaker is set to testify before the House Energy and Commerce Committee on the rising prices of insulin later in the day.

  • Why Eli Lilly (LLY) is a Great Dividend Stock Right Now
    Zacks9 days ago

    Why Eli Lilly (LLY) is a Great Dividend Stock Right Now

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

  • Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice
    Zacks9 days ago

    Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice

    Lilly (LLY) could produce exceptional returns because of its solid growth attributes.

  • Reuters9 days ago

    Sanofi to cut U.S. insulin costs for some patients to $99 per month

    Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication. Sanofi announced the plan hours before one of its executives was set to testify before a congressional committee on the rising prices of insulin. Executives from the other leading insulin producers - Eli Lilly & Co and Novo Nordisk A/S - will also testify.

  • Heated debate over high drug costs returns to Capitol Hill
    Associated Press10 days ago

    Heated debate over high drug costs returns to Capitol Hill

    Patient bills, competition and secrecy shared the spotlight Tuesday as pharmacy benefit managers testified before Congress about prescription drug prices.

  • United Therapeutics Discontinues PAH Drug After Study Fails
    Zacks10 days ago

    United Therapeutics Discontinues PAH Drug After Study Fails

    United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.

  • Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men
    Zacks13 days ago

    Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men

    Pfizer's (PFE) blockbuster breast cancer medicine gets FDA approval to treat men. The approval for the expanded indication is based predominately on real-world data.

  • Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig
    Zacks14 days ago

    Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig

    Novartis (NVS) sues Amgen as the latter issues termination notice for migraine drug.

  • Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval
    Zacks14 days ago

    Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval

    The index notched up another week of gains riding on optimism over the increasing likelihood of a U.S.-China trade deal.